Brief: Neoleukin Therapeutics Announces First Patient Treated In Combination Arm Of Phase 1 Trial Evaluating NL-201 In Combination With Keytruda
16/05/2022 13:18
May 16 (Reuters) - Neoleukin Therapeutics Inc NLTX.O :
* NEOLEUKIN THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN
COMBINATION ARM OF PHASE 1 TRIAL EVALUATING NL-201 IN
COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)
Source text for Eikon: ID:nGNX3B7GgJ
Further company coverage: NLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable